These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 16395746

  • 21. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 22. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA.
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [Abstract] [Full Text] [Related]

  • 23. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T.
    J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
    [Abstract] [Full Text] [Related]

  • 24. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 25. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, Keenan G.
    Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
    [Abstract] [Full Text] [Related]

  • 26. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF.
    J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
    [Abstract] [Full Text] [Related]

  • 27. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J.
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [Abstract] [Full Text] [Related]

  • 28. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 29. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
    Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I.
    J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748
    [Abstract] [Full Text] [Related]

  • 30. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C.
    Arthritis Res Ther; 2004 Jan; 6(3):R264-72. PubMed ID: 15142273
    [Abstract] [Full Text] [Related]

  • 31. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
    Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner I.
    Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
    [Abstract] [Full Text] [Related]

  • 32. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.
    Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F.
    Arthritis Res Ther; 2006 Jun; 8(4):R112. PubMed ID: 16978395
    [Abstract] [Full Text] [Related]

  • 33. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T, Pincus T.
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [Abstract] [Full Text] [Related]

  • 34. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
    Stern R, Wolfe F.
    J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
    [Abstract] [Full Text] [Related]

  • 35. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 36. Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation.
    Novak S, Anić B, Anić F, Cerovac M, Cikeš N.
    Acta Dermatovenerol Croat; 2011 Mar; 19(3):156-60. PubMed ID: 21933639
    [Abstract] [Full Text] [Related]

  • 37. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A.
    Rheumatology (Oxford); 2011 Aug; 50(8):1445-52. PubMed ID: 21427177
    [Abstract] [Full Text] [Related]

  • 38. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
    Svenson M, Geborek P, Saxne T, Bendtzen K.
    Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
    [Abstract] [Full Text] [Related]

  • 39. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.
    Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL.
    J Rheumatol; 2007 May; 34(5):952-7. PubMed ID: 17444589
    [Abstract] [Full Text] [Related]

  • 40. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.